5 results about "Vasoactive intestinal peptide" patented technology

This invention provides a kit comprising: (1) a pharmaceutical composition containing a therapeutically effective amount of eugenol hydrochloride and a pharmaceutically acceptable carrier; and (2) a detection reagent for detecting vasoactive intestinal peptide (VIP) mRNA and / or protein. This invention reveals for the first time that eugenol hydrochloride (HH) has a highly effective therapeutic effect on specific Parkinson's disease patients characterized by abnormally elevated VIP levels. The pharmaceutical composition and kit of this invention can specifically reduce the expression of pro-inflammatory VIP, thereby precisely intervening in the VIP-mediated microglial-related neuroinflammatory pathway, thus significantly treating Parkinson's disease and providing a novel targeted treatment option for the clinical intervention of Parkinson's disease.

The present invention relates to methods and compositions for treating muscle diseases and disorders. The invention provides methods for treating muscle myopathies, including muscular dystrophy and cardiomyopathy, by administering stable, long-acting therapeutic agents for vasoactive intestinal peptides. These agents include one or more elastin-like peptides and can be administered at low doses.

Artificial expression constructs are provided.SOLUTION: Artificial expression constructs are provided that selectively regulate gene expression in selected central nervous system cell types. Such artificial expression constructs can be used to selectively express synthetic genes or alter the expression of genes in inhibitory neocortical GABAergic neurons, including somatostatin GABAergic neurons, parvalmine GABAergic neurons, vasoactive intestinal peptide GABAergic neurons, Lamp5GABA GABAergic neurons, or in some instances astrocytes.SELECTED DRAWING: Figure 2-1

The invention discloses a circular RNA vaccine based on a vasoactive intestinal peptide delivery system and application of the circular RNA vaccine, and relates to the field of RNA vaccines. Comprising vasoactive intestinal peptide VIP serving as a delivery carrier and circular RNA for coding a respiratory syncytial virus RSVpreF antigen, and the vasoactive intestinal peptide VIP and the circular RNA form a compound through non-covalent linkage; the vasoactive intestinal peptide VIP is a VIP-EGFP-N fusion protein. According to the invention, the function of the VIP as a high-efficiency cell-penetrating peptide is explored and verified for the first time, and the VIP is combined with a circular RNA molecule of a coding RSV key antigen protein preF to construct a safe, stable and high-efficiency RSV vaccine, so that the technical bottlenecks of poor stability of the existing mRNA vaccine, complex and low-efficiency LNP delivery system, insufficient immunogenicity or poor safety of the traditional RSV vaccine and the like are solved.

The polypeptide feed is prepared from the following raw materials in percentage by mass: 35%-40% of a plant crude extract, 35%-45% of a protein source, 5%-8% of microbial flora and 15%-20% of a fermentation auxiliary material, wherein the plant extract is prepared from the following raw materials in percentage by mass: 50% of an astragalus membranaceus crude extract, 30% of a codonopsis pilosula crude extract and 20% of an angelica sinensis crude extract. The feed contains various plant and animal-derived amino acids, can supplement various nutrients in animal bodies, maintain amino acid balance, and is beneficial to enhancing protein fat absorption, promoting muscle and fat growth and improving meat quality and flavor, and meanwhile, the rich peptide contains various beneficial bacteria and free fatty acids, so that vasoactive intestinal peptide causes vasodilatation of mesentery, and the meat quality and flavor are improved. Protease and digestive enzymes are secreted in quantity, intestinal tract movement is enhanced, digestive absorption and anabolism of the body are enhanced, and therefore growth of the body is promoted.